Considering the various health problems associated with obesity in dogs, including renal diseases, joint disorders, and skin diseases, effective management strategies and guidelines are urgently needed. This situation has led to a growing demand for veterinary medications aimed at addressing obesity in dogs. However, the field faces a significant hurdle due to the absence of standardized guidelines for assessing the effectiveness of these anti-obesity medications in dogs. In response to this gap, the Animal and Plant Quarantine Agency (APQA) in Korea has made a crucial step by introducing clinical trial guidelines to evaluate the efficacy of treatments for canine obesity, specifically aimed at approving veterinary medicinal products. The guidelines outlined the selection criteria for target dogs, highlighting the importance of consistency within the control and treated groups. Treatment efficacy is subsequently evaluated by physical examination, body fat reduction, and biochemical indicators. In addition, the guidelines cover dosage and administration, monitoring after dosing, and statistical analysis. By doing so, this guideline not only highlights the significance of the APQA’s initiative in improving the care of obese dogs but also provides practical insights to enhance the standardization and effectiveness of clinical trials in veterinary medicine.